RongCan Biotech

Rongcan Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of mRNA therapeutics and vaccines. The company utilizes its proprietary lipid nanoparticle (LNP) delivery platform to address the challenges of nucleic acid delivery, focusing on stability and tissue-specific targeting. Its pipeline includes candidates for infectious diseases, such as COVID-19 and respiratory syncytial virus (RSV), as well as innovative programs in oncology and rare diseases. Rongcan has successfully raised significant venture capital from prominent investors like Sequoia China to advance its technology from discovery through clinical development. The company maintains integrated capabilities in mRNA sequence optimization, LNP formulation, and pilot-scale manufacturing. By leveraging its deep expertise in delivery science, Rongcan aims to become a leader in the global mRNA medicine landscape.